Sonodynamic therapy for the treatment of atherosclerosis

Yan Zhang1, Ying Yang2, Yudi Feng1

  • 1The Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Insights

Sonodynamic therapy (SDT) shows promise for treating atherosclerosis (AS) by inhibiting plaque progression and stabilizing arterial inflammation. This review details SDT

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering
  • Oncology

Background:

  • Atherosclerosis (AS) is a chronic inflammatory arterial disease with high mortality and disability rates despite current treatments.
  • Sonodynamic therapy (SDT) emerges as a promising non-invasive therapeutic approach for AS.
  • SDT offers localized treatment for inhibiting atherosclerotic progression and stabilizing plaques.

Purpose of the Study:

  • To review ultrasonic parameters and sonosensitizers used in SDT for AS.
  • To elaborate on the therapeutic effects and mechanisms of SDT in AS.
  • To discuss the safety and establish a framework for future SDT research in AS.

Main Methods:

  • Review of existing literature on SDT for atherosclerosis.
  • Analysis of ultrasonic parameters and sonosensitizers.
  • Elaboration on SDT's effects on cellular and molecular components of atherosclerotic plaques.

Main Results:

  • SDT demonstrates therapeutic effects on apoptosis and autophagy in AS cells, particularly macrophages.
  • SDT influences macrophages, T lymphocytes, neovascularization, smooth muscle cells, lipids, and extracellular matrix within plaques.
  • Non-lethal SDT strategies and efferocytosis modulation are discussed.

Conclusions:

  • SDT is a promising non-invasive therapy for atherosclerosis, with established effects on plaque components and cellular processes.
  • Further research is needed to optimize SDT parameters and sonosensitizers for clinical application in AS.
  • This review provides a comprehensive framework for future research into SDT for atherosclerosis.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421